Pyogenic spondylitis caused by *Klebsiella pneumoniae*: should the possibility of hypervirulent *Klebsiella pneumoniae* be considered?

Joo-Hee Hwang¹,², Seung Yeob Lee²,³, Jaehyeon Lee²,³* and Jeong-Hwan Hwang¹,²*

**Abstract**

**Background** *Klebsiella pneumoniae* is rare but the second most common causative agent among gram-negative bacteria that cause pyogenic spondylitis. However, there are no available studies on the serotype, virulence factors, and clinical characteristics associated with *K. pneumoniae*-caused pyogenic spondylitis. Accordingly, we investigated the clinical characteristics of pyogenic spondylitis, K1 and K2 serotypes, and virulence factors of *K. pneumoniae*.

**Methods** We reviewed the microbiological reports of specimens collected between January 2014 and December 2019 as well as the medical records of patients with pyogenic spondylitis caused by *K. pneumoniae*. We also evaluated K1 and K2 serotypes and the virulent genes *rmpA*, *iutA*, *mrkD*, *ybtS*, *entB*, and *kfu*. Strains that possessed *rmpA* and *iutA* were defined as hypervirulent *K. pneumoniae*.

**Results** Six patients with pyogenic spondylitis caused by *K. pneumoniae* were enrolled in the study. The capsular serotypes K1 and K2 were present in 66.7% (4/6) of cases, and the hypervirulent strains were present in 88.3% (5/6) of cases. All patients had community-acquired infections, and all strains isolated were susceptible to antimicrobial agents. Intravenous antibiotic treatment continued for 2–7 weeks, and no patient underwent decompressive operation or surgical debridement. There was no recurrence. One patient died from pneumonia with a septic lung.

**Conclusion** Hypervirulent *K. pneumoniae* is a rare but possible causative agent associated with pyogenic spondylitis.

**Keywords** Pyogenic spondylitis, *Klebsiella pneumoniae*, Hypervirulence
Background
Recent years have seen a notable increase in cases of pyogenic spondylitis, especially in elderly populations [1–3]. This rise is attributable to various risk factors prevalent in this group, such as an increased frequency of immunodeficiency disorders and chronic diseases, and more frequent use of invasive spinal procedures [1–3]. The increased use of advanced diagnostic tools such as magnetic resonance imaging or bone scans have also contributed to improved early detection and diagnosis of the disease [2]. Pyogenic spondylitis is associated with a significant mortality rate and frequent relapse [4]. Patients with pyogenic spondylitis also suffer from residual disability, severe functional sequelae, and long-term antibiotic treatment [4].

The most common organism responsible for pyogenic spondylitis infections is Staphylococcus aureus [5]. The proportion of gram-negative organisms is 10–30%, compared to 60-80% of gram-positive bacteria [6–10]. Among the gram-negative bacteria, Escherichia coli is the most common, followed by Klebsiella pneumoniae, which accounts for 1–5% of all infections [6–10]. Intra-abdominal and urinary tract infections (UTIs) are the most common source of pyogenic spondylitis caused by gram-negative bacteria [8, 11].

K. pneumoniae present in a healthcare setting, known as “classic K. pneumoniae” (cKP), has been reported to be a main causative agent of pneumonia, UTI, and bloodstream infections in immunocompromised patients [12]. “Hypervirulent K. pneumoniae” (hvKP), in contrast, tends to be contracted in the community, cause more invasive or metastatic infections, including liver abscess, endophthalmitis, septic lung, osteomyelitis, pyomyositis, and necrotizing fasciitis, and is responsible for more of the infections observed in relatively healthy individuals [12]. To date, 79 capsular types have been identified and associated with various Klebsiella species, with the K1 and K2 serotypes known to be associated with hypervirulent features [13, 14]. One recent study showed that virulence genes, such as iroB, iucA, peg-344, rmpA, and rmpA2, closely correlate with or are determinant factors of hvKP [15].

K. pneumoniae is well-known for its role in pneumonia and other HCA infections [16], but comparatively less information is available concerning pyogenic spondylitis caused by K. pneumoniae of the K1 and K2 serotypes or possessing virulent genes. Therefore, we examined the clinical implications of pyogenic spondylitis caused by K. pneumoniae, as well as its microbiological features such as the K1 and K2 serotypes, and the virulence genes iutA, rmpA, ybtS, entB, kfu, mrkD, and allS.

Methods
Study setting and data collection
We conducted a retrospective study at a 1,200-bed tertiary hospital at Jeonbuk National University Hospital in Jeonju, Korea. We reviewed all medical records of patients aged ≥19 years who were diagnosed with pyogenic spondylitis, and identified all cases in which K. pneumoniae was isolated from blood cultures, tissue cultures, or pus cultures between January 2014 and December 2019. The data collected from each subject included demographic characteristics, clinical signs and symptoms, underlying comorbidities, microbiological data, radiographic findings, laboratory data, surgical treatment, and clinical outcomes. Diagnosis of pyogenic spondylitis was made according to clinical, radiological, and microbiological criteria [17].

Definition
Healthcare-associated infection (HCA) is defined as a K. pneumoniae infection that develops within 48 h of hospital admission in patients (a) hospitalized for two or more days in the preceding 90 days, (b) that received intravenous medication or home wound care in the previous 30 days, (c) that received hemodialysis, or (d) that reside in a nursing home or long-term care facility [18]. A community-acquired infection is one that occurs in patients with no risk factors for HCA infection for whom the first positive culture for K. pneumoniae was identified within 48 h of admission [18]. A hospital-acquired infection is one that is diagnosed through a positive culture for K. pneumoniae over 48 h after admission [18].

The neurologic staging is defined as follows: stage 0, no pain; stage 1, back pain at the level of the involved spine; stage 2, radiating pain from the involved spine; stage 3, motor weakness, sensory deficit, and bladder and bowel dysfunction; and stage 4, paralysis [19]. Sequelae are defined as persisting pyogenic spondylitis-associated signs and symptoms that last at least 12 months after the completion of treatment [11].

Microbiological evaluation and antimicrobial susceptibility
All laboratory tests were performed consistent with routine clinical practice. For cultures, all samples were inoculated onto blood agar and MacConkey agar plates in a 35 °C incubator for 16 to 24 h. The BacT/Alert 3D system (bioMérieux, Durham, NC, USA) was used for blood cultures. The isolated bacteria were identified using a VitekMS system (bioMérieux, Hazelwood, MO, USA) and antimicrobial susceptibility tests were conducted using Vitek 2 AST 211 cards (bioMérieux, Marcy-l’Étoile, France) and interpreted using the VITEK 2 identification system [20]. Multiplex polymerase chain reaction was used to detect K1 and K2 capsular serotypes and virulence genes. Primer sets for magA (wzy-like polymerase
specific to K1 capsular serotype), wzi (the gene specifying the K2 capsular serotype), and other virulence genes (ybtS, entB, allS, kfu, iutA, mrkD, and rmpA) have been described previously [21]. hvKP is considered detected when both rmpA and iutA genes are positive [13].

Results
Over the course of the study a total of six patients with pyogenic spondylitis caused by K. pneumoniae were identified; five males and one female (Table 1). The six patients ranged in age from 60 to 84 years. Among the underlying diseases, diabetes mellitus (DM) was confirmed in two of six patients while colon cancer was confirmed in one patient. All patients had community-acquired infections. The sources of infection included a UTI in one patient and a liver abscess in another. All patients had a neurologic staging of 1 or 2. The thoracic spine was involved in two patients while the lumbosacral spine was involved in four cases. Bacteremia was also detected in four patients. The intravenous administration of antimicrobial agents such as ceftriaxone, cefotaxime, ceftazidime, ciprofloxacin, and meropenem continued for between 2 and 7 weeks. After intravenous antibiotic treatment, oral fluoroquinolone was prescribed. No patient underwent decompressive operation or surgical debridement as a result of neurologic complications during antibiotic treatment. Sequelaes were observed in two cases but there was no recurrence. Among the six cases, the K1 and K2 serotypes were observed in four cases while hypervirulent strains, which have rmpA and iutA,

| Table 1 | The clinical features of patients with pyogenic spondylitis caused by Klebsiella pneumoniae |
|---------|----------------------------------------------------------------------------------------|
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
| Age    | 67     | 60     | 52     | 84     | 61     | 78     |
| Sex    | M      | M      | F      | M      | M      | M      |
| Underlying disease | Colon cancer | DM, hypertension | No | No | Liver cirrhosis, CKD | DM |
| Type of infection | CAI | CAI | CAI | CAI | CAI | CAI |
| Spinal procedure | Verteoplasty | Not done | Not done | Not done | Not done | Not done |
| Prosthesis | Not done | Not done | Not done | Not done | Not done | Not done |
| Source of infection | No | No | No | UTI | No | Liver abscess |
| Neurologic staging | Stage 1 | Stage 1 | Stage 1 | Stage 2 | Stage 2 | Stage 2 |
| Radiologic finding | Involved area | T-spine | T-spine | L-S spine | L-S spine | L-S spine |
| | Involved number | 1 to 2 VB | 1 to 2 VB | 1 to 2 VB | 1 to 2 VB | 1 to 2 VB |
| Combined abscess | Epidual abscess | No | No | Epidual, psoas abscess | Epidual, psoas abscess | Epidual, psoas abscess |
| Laboratory finding | WBC(10^3/µL) | 15.00 | 9.37 | 18.57 | 22.15 | 8.03 | 7.97 |
| | CRP(mg/L) | 22 | 129 | 362 | 204 | 215 | 281 |
| | Procalcitonin(ng/mL) | Not checked | 0.26 | 12.41 | 0.85 | 74.76 | 62.78 |
| | Bacteremia | No | No | Yes | Yes | Yes | Yes |
| | Tissue culture and sensitivity | Yes | Yes | Yes | Yes | Yes | Yes |
| | Symptoms and signs | Fever | No | Yes | Yes | Yes | Yes |
| | | Back pain | Yes | Yes | Yes | Yes | Yes |
| | | Metastatic infection | No | No | Pneumonia | Pneumonia | No | No |
| | | Outcome | 30-day mortality | Alive | Alive | Alive | Dead | Alive | Alive |
| | | | Sequelaes | No | Yes | No | N.A | Yes | Yes |
| | | | Recur | No | No | No | N.A | No | No |
| | | | Treatment | Antibiotics | CAZ IV | CRO IV, LVX PO | CRO IV, CIP PO | VAN IV, MEM IV | CTX IV, CIP PO | CRO IV, CIP PO |
| | | | | Duration | 6 weeks | 4 weeks, 3 months | 7 weeks, 2 months | 2 weeks | 2 weeks, 7 months | 7 weeks, 3 months |
| | | | | Operation | Not done | Not done | Not done | Not done | Not done | Not done |

CAI, community acquired infection; CKD, chronic kidney disease; DM, diabetes mellitus; UTI, urinary tract infection; VB, vertebral body; WBC, white blood cells; CRP, C-reactive protein; CAZ, ceftazidime; CRO, ceftriaxone; LVX, levofloxacin; CIP, ciprofloxacin; VAN, vancomycin; MEM, meropenem; CTX, cefotaxime; IV, intravenous, PO, oral
were found in five patients (Table 2). One patient died owing to aggravation of septic lung, he did not, however, have the hypervirulent strain or the K1 or K2 serotype. Antimicrobial susceptibility tests showed that all isolates were sensitive to all tested antibiotics (aminoglycosides, ampicillin, sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, ceftazidime, ertapenem, gentamicin, levofloxacin, meropenem, piperacillin-tazobactam, and tigecycline).

Discussion
This study suggests that *K. pneumoniae* is a clinically rare but significant pathogen of pyogenic spondylitis. To our knowledge, this is the first study to investigate K1 and K2 serotypes and virulence factors of pyogenic spondylitis-causing *K. pneumoniae*. Of the six strains tested, four were K1 and K2 serotypes while five were hypervirulent strains, suggesting that most *K. pneumoniae* that causes pyogenic spondylitis is hvKP.

Consistent with other studies concluding that intra-abdominal infections and UTI predisposing factors for pyogenic spondylitis caused by gram-negative bacteria, the UTI in Case 4 and liver abscess in Case 6 were identified as presumed sources of pyogenic spondylitis [8, 11]. The primary location of vertebral involvement, the number of invaded vertebral bodies, and the rate of positive blood culture observed in these patients were consistent with previous studies [8, 11]. Although there is no officially-recognized recommended treatment period, 8 weeks has been suggested as appropriate to prevent recurrence [11]. In this study, the intravenous antibiotics used included ceftriaxone, cefotaxime, ceftazidime, ciprofloxacin, and meropenem. The period of intravenous antibiotic administration was 2–7 weeks, after which oral fluoroquinolone was maintained. In no case was recurrence observed after the conclusion of treatment. Because fluoroquinolone has a high oral bioavailability and good penetration into bone tissue, oral fluoroquinolone may be a good therapeutic option for prolonged antibiotic therapy [11]. For infectious spondylitis caused by gram-negative bacteria, 49.2% of patients underwent surgery during antibiotic treatment [11]. This antibiotics used in Park et al’s study were fluoroquinolone and third-generation cephalosporin, which are similar to the antibiotics used in our study [11].

No standard definition of hvKP has yet been established. Hypervirulence in *K. pneumoniae* can be defined as the ability of the organism to cause invasive infections in healthy adults through metastatic dissemination from a primary infection site [22]. Diverse virulence factors are associated with a hypervirulent phenotype [12], including the production of hypercapsule, lipopolysaccharide, siderophores, and fimbriae (pili) [12]. Hypervirulence as a phenomenon is not thought to be associated with a single gene, but rather appears to be the result of complex interactions between multiple genetic determinants [13, 22]. The aerobactin gene cluster *iucABCD*, aerobactin transporter *iutA* (biosynthetic genes for the siderophore aerobactin), and *rmpA* or *rmpA2* (which trigger hypercapsule production) have been regarded as good diagnostic candidates for hypervirulence [13]. In our study, five of the six strains were hypervirulent based on this definition, and in each case the strain was the causative pathogen of the infectious spondylitis. Although we were limited by the small number of samples available for testing, our findings do suggest that the hypervirulent strain may be more associated with pyogenic spondylitis than the classic strain. A study that compares the frequency of hvKP and cKP-induced pyogenic spondylitis with a greater number of study subjects is needed to confirm this hypothesis.

*K. pneumoniae* is a well-known multidrug-resistant bacteria with emerging carbapenemase-producing strains. In contrast, hvKP remains susceptible to most clinically used antibiotics [12]. All six patients studied showed community-acquired infection, and each of the identified strains proved to be susceptible to all antimicrobial agents studied. However, the emergence of hvKP-producing extended spectrum beta-lactamase (ESBL) or carbapenemase has been reported [23, 24]. As a pyogenic spondylitis treatment, the administration of intravenous antibiotics or highly bioavailable oral agents is recommended to continue for longer than 6 weeks [25]. If hvKP

### Table 2

| Serotype         | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 |
|------------------|--------|--------|--------|--------|--------|--------|
| Virulent factor  |        |        |        |        |        |        |
| rmpA             | Positive | Positive | Positive | Negative | Positive | Positive |
| iutA             | Positive | Positive | Positive | Negative | Negative | Positive |
| allS             | Negative | Positive | Positive | Positive | Negative | Positive |
| entB             | Positive | Positive | Positive | Positive | Negative | Positive |
| kfu              | Negative | Positive | Positive | Positive | Negative | Positive |
| mrkD             | Positive | Positive | Positive | Positive | Negative | Positive |
| ybrS             | Positive | Positive | Positive | Positive | Negative | Positive |
strains producing ESBL or carbapenemase cause pyogenic spondylitis, the selection of antimicrobial agents available in these cases is very limited, and it is unlikely that those available would exert a sufficient therapeutic effect. Moreover, the treatment of multiple sites infected by hvKP, including metastatic infections, is a therapeutic challenge owing to the poor penetration of certain antimicrobial agents when used to treat pyogenic spondylitis [13]. Although ESBL or multidrug-resistant hvKP were reported neither in this study nor previous studies concerning pyogenic spondylitis, continuous surveillance is required.

This study had some limitations. Salmochelin (iroA gene cluster, iroBCDE) and peg-344 were recently reported to be significant virulent factors specific to hvKP, though these were not tested in this study [15] nor did we test for the presence of rmpA2. Another limitation was the small number of cases, though we note that all obtainable cases over a six-year period were included. Finally, we investigated only some virulence factors, and declined to explore any virulence factors through an animal study. While hypervirulence could be demonstrated easily in a mouse infection model or Galleria mellonella infection model, we were unable to perform these tests. We defined microbial hypervirulence exclusively by reference to the presence of virulence genes [26].

**Conclusion**

This study suggests that hvKP is a rare but possible causative agent associated with pyogenic spondylitis. Although *K. pneumoniae* infection constitutes a relatively minor proportion of all cases, its clinical importance should be evaluated through larger studies, as treatment can become more complicated when resistance to antimicrobial agents increases.

**Abbreviations**

ckP classic *K. pneumoniae*

hvKP hypervirulent *K. pneumoniae*

HCA healthcare-associated infection

UTI urinary tract infection

ESBL extended spectrum β lactamase

**Acknowledgements**

We thank Mallikarjun Handigund, Ph.D., Department of Laboratory Medicine, Jeonbuk National University Medical School and Hospital, for his contribution in generating the data for this study.

**Author contribution**

All authors meet the ICMJE authorship criteria. JeongHH and JHL designed the study, analyzed and interpreted the patient and microbiological data, performed the literature search, and prepared the manuscript. JHL and SYL analyzed and interpreted the microbiological data. JooHH and JeongHH participated in the collection of patient’s data and data interpretation. JooHH and SYL wrote the paper. All authors contributed to the drafting of the manuscript, and read and approved the final version.

**Funding**

This paper was supported by research funds for newly appointed professors of Jeonbuk National University in 2021. And, this paper was supported by Fund of Biomedical Research Institute, Jeonbuk National University Hospital. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was approved and conducted consistent with the guidelines established by the Institutional Review Board of the Jeonbuk National University Hospital (IRB no.: CUH 2021-11-006). Institutional Review Board of the Jeonbuk National University Hospital waived the need for specific informed consent from study participants because this study data was anonymized, so could not identify the subjects.

**Consent for publication**

Not applicable.

**Conflict of interest**

The authors of this study declare no commercial relationships and no conflicts of interest.

**References**

1. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65(Suppl 3):ii1–24.

2. Cottle L, Riordan T. Infectious spondylodiscitis. J Infect. 2008;56(6):401–12.

3. Kehrer M, Pedersen C, Jensen TG, Lassen AT. Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect. 2014;68(4):313–20.

4. Mylona E, Samarakos M, Kakalou E, Fanourgakis P, Skoutelis A. Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics. Semin Arthritis Rheum. 2009;39(1):110–7.

5. Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010;362(11):1022–9.

6. Russo A, Graziano E, Carmeluttii A, Sponza M, Cadeo B, Santor A, Righi E, Bassetti M. Management of vertebral osteomyelitis over an eight-year period: The UPDROVE (UDine PROtocol on VErtebral osteomyelitis). Int J Infect diseases. UDI: official publication Int Soc Infect Dis. 2019;89:116–21.

7. Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YR, Kim SH, Lee SO, et al. Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertebral Osteomyelitis at Low Risk and High Risk of Recurrence. Clin Infect diseases: official publication Infect Dis Soc Am. 2016;62(10):1262–9.

8. Kang SJ, Jang HC, Jung SI, Choe PG, Park WB, Kim CJ, Song KH, Kim ES, Kim HB, Oh MD, et al. Clinical characteristics and risk factors of pyogenic spondylitis caused by gram-negative bacteria. PLoS ONE. 2015;10(5):e0127126.

9. Chang WS, Ho MW, Lin PC, Ho CM, Chou CH, Lu MC, Chen YJ, Chen HT, Wang JH, Chi CY. Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis. 12-year experience from a tertiary hospital in central Taiwan. J Microbiol Immunol Infect. 2018;51(2):235–42.

10. Kim NJ. Microbiologic Diagnosis of Pyogenic Spondylodiscitis. Infect Chemother. 2021;53(2):238–46.

11. Park KH, Cho OH, Jung M, Suk KS, Lee JH, Park JS, Ryu KN, Kim SH, Lee SO, Choi SH, et al. Clinical characteristics and outcomes of hematogenous pyogenic vertebral osteomyelitis caused by gram-negative bacteria. J Infect. 2014;69(1):42–50.

12. Paciosa MK, Meccas J. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol biol reviews: MMBR. 2016;80(3):629–61.

13. Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clinical microbiology reviews 2019, 32(3).

14. Pan YJ, Lin TL, Chen CT, Chen YY, Hseih PF, Hsu CR, Wu MC, Wang JT. Genetic analysis of capsular polysaccharide synthesis gene clusters in 79 capsular types of Klebsiella spp. Sci Rep. 2015;5:15573.
15. Russo TA, Olson R, Fang CT, Stoesser N, Miller M, MacDonald U, Hutson A, Barker JH, La Hoz RM, Johnson JR. Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae. Journal of clinical microbiology. 2018;56(9).

16. Hwang JH, Handigund M, Hwang JH, Cho YG, Kim DS, Lee J. Clinical Features and Risk Factors Associated With 30-Day Mortality in Patients With Pneumonia Caused by Hypervirulent Klebsiella pneumoniae (hvKP). Ann Lab Med. 2020;40(6):481–7.

17. Eren Gök S, Kap饃oğlu E, Celikbaş A, Ergonüül O, Baykam N, Ergülü M, Dokuzoğuz B. Vertebral osteomyelitis: clinical features and diagnosis. Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis. 2014;2010:1055–60.

18. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JR, Lamm W, Clark C, MacFarquhar J, Walton AL, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791–7.

19. Darouiche RO. Spinal epidural abscess. N Engl J Med. 2006;355(19):2012–20.

20. CLSI. Performance standards for antimicrobial susceptibility testing. 2018.

21. Compain F, Babosan A, Brisse S, Genel N, Audo J, Allouf F, Kassiss-Chikhani N, Arlet G, Decie D. Multiplex PCR for detection of seven virulence factors and K1/K2 capsular serotypes of Klebsiella pneumoniae. J Clin Microbiol. 2014;52(12):4377–80.

22. Catalán-Nájera JC, Garza-Ramos U, Barrios-Camacho H. Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes? Virulence. 2017;8(7):1111–23.

23. Banerjee T, Wangkheimayum J, Sharma S, Kumar A, Battacharjee A. Extensively Drug-Resistant Hypervirulent Klebsiella pneumoniae From a Series of Neonatal Sepsis in a Tertiary Care Hospital, India. Front Med (Lausanne). 2021;8:645955.

24. Tang M, Kong X, Hao J, Liu J. Epidemiological Characteristics and Formation Mechanisms of Multidrug-Resistant Hypervirulent Klebsiella pneumoniae. Front Microbiol. 2020;11:581543.

25. Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM, 3rd, Petermann GW, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect diseases: official publication Infect Dis Soc Am. 2015;61(6):e26–46.

26. Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015;83(8):3325–33.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.